Table 2 Comparison of biopsy strategies on lesion and patient level.

RS—Lesions

Cancer missed (total)

21 (36.2)

0.003

12 (20.7)

0.018

6 (10.3)

0.07

58

Cancer missed (> ISUP I)

24 (53.3)

0.001

15 (33.3)

0.008

7 (15.6)

0.052

45

Gleason upgrade

34 (58.6)

–

22 (37.9)

–

12 (20.7)

–

58

Change in definitive treatment¹

24 (41.4)

 < 0.001

15 (25.9)

0.004

7 (12.1)

0.15

58

Insufficient staging²

11 (19.0)

0.028

5 (8.6)

0.3

3 (5.2)

0.56

58

RS—Patients

Cancer missed (total)

17 (37.0)

0.006

10 (21.7)

0.03

5 (10.9)

0.09

46

Cancer missed (> ISUP I)

18 (50)

0.003

12 (33.3)

0.01

5 (13.9)

0.08

36

Gleason upgrade

28 (60.9)

–

19 (41.3)

–

10 (21.7)

–

46

Change in definitive treatment¹

18 (39.1)

 < 0.001

12 (26.1)

0.01

5 (10.9)

0.24

46

Insufficient staging²

10 (21.7)

0.026

5 (10.9)

0.28

3 (6.5)

0.52

46

WCS—Lesions

Cancer missed (total)

35 (60.3)

 < 0.001

26 (44.8)

0.002

17 (29.3)

0.007

58

Cancer missed (> ISUP I)

33 (73.3)

0.003

28 (62.2)

0.002

20 (44.4)

0.003

45

Gleason upgrade

50 (86.2)

–

45 (77.6)

–

35 (60.3)

–

58

Change in definitive treatment¹

33 (56.9)

 < 0.001

28 (48.3)

 < 0.001

20 (34.5)

 < 0.001

58

Insufficient staging²

18 (31.0)

 < 0.001

16 (27.6)

0.001

12 (20.7)

0.02

58

WCS—Patients

Cancer missed (total)

28 (60.9)

 < 0.001

21 (45.7)

0.002

15 (32.6)

0.008

46

Cancer missed (> ISUP I)

25 (69.4)

 < 0.001

21 (58.3)

0.002

17 (47.2)

0.004

36

Gleason upgrade

41 (89.1)

–

36 (78.3)

–

28 (60.9)

–

46

Change in definitive treatment¹

25 (54.3)

 < 0.001

21 (45.7)

 < 0.001

17 (37.0)

 < 0.001

46

Insufficient staging²

15 (32.6)

 < 0.001

14 (30.4)

0.002

11 (23.9)

0.01

46